NCT07552974: Phase 2 CBD Trial for BJJ Athletes
Summary
A Phase 2 randomized controlled trial (NCT07552974) will evaluate CBD Isolate at 100mg twice daily versus placebo in 24 Brazilian Jiu-Jitsu athletes. The study targets inflammatory cytokine modulation (IL-6, TNF-α, IL-8, IL-1β, IL-10), delayed-onset muscle soreness, sleep quality, and pain in a population where combat-sport injury prevalence reaches 28%. No regulatory submission or compliance action is associated with this trial registration.
“Cannabidiol (CBD), a non-psychotomimetic phytocannabinoid derived from Cannabis sativa, has emerged as a promising therapeutic agent due to its anti-inflammatory, analgesic, anxiolytic, and neuroprotective properties.”
About this source
ClinicalTrials.gov is the NIH-run registry of every clinical trial conducted in the United States, plus most international trials sponsored by US-based companies or institutions. By federal law, sponsors must register Phase 2 through Phase 4 studies before enrolling patients and post results within a year of completion. This feed tracks every new trial registration and study update, around 700 a month: drug interventions, device studies, behavioral protocols, observational research. Watch this if you scout drug candidates moving into mid or late-stage development, monitor competitor pipelines, or follow rare disease research where new trials signal patient hope. GovPing parses sponsor, phase, intervention, and target indication on each entry.
What changed
ClinicalTrials.gov registration for a Phase 2 randomized, placebo-controlled trial examining CBD Isolate supplementation in Brazilian Jiu-Jitsu athletes. The trial will assess CBD's effects on pro- and anti-inflammatory cytokines, delayed-onset muscle soreness, pain, sleep quality, and overall quality of life using a CBD Isolate 100mg BID dosing regimen versus placebo in approximately 24 participants. The rationale cites preclinical evidence of CBD's anti-inflammatory activity through NF-κB and NLRP3 pathway inhibition and clinical potential to attenuate DOMS without NSAID-associated adverse effects.
For sports medicine researchers, athletic trainers, and sports medicine practitioners, this trial represents an emerging evidence base for cannabinoid-based recovery strategies in contact sports. The 28% injury prevalence cited for combat sports and the 23.4% reported cannabis use rate among athletes highlight the translational gap the study seeks to address. Findings, once published, may inform future sports medicine protocols but do not create any compliance obligation for healthcare providers or sports organizations at this time.
Archived snapshot
Apr 28, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
CBD Supplementation in Brazilian Jiu-Jitsu Athletes
Phase 2 NCT07552974 Kind: PHASE2 Apr 27, 2026
Abstract
Brazilian Jiu-Jitsu (BJJ) is a high-intensity martial art that imposes significant physical and physiological demands on practitioners, including rigorous training and frequent competitions, which can result in chronic inflammation, delayed-onset muscle soreness (DOMS), sleep disturbances, and reduced quality of life. Effective recovery strategies are essential to optimize athletic performance and longevity in the sport.
Cannabidiol (CBD), a non-psychotomimetic phytocannabinoid derived from Cannabis sativa, has emerged as a promising therapeutic agent due to its anti-inflammatory, analgesic, anxiolytic, and neuroprotective properties.
Preclinical studies indicate that CBD modulates inflammatory pathways, such as inhibition of NF-κB and NLRP3, thereby reducing pro-inflammatory cytokines such as IL-6, TNF-α, IL-8, and IL-1β, while increasing the anti-inflammatory cytokine IL-10.
In clinical contexts, CBD has shown potential to attenuate DOMS and improve sleep without the adverse effects associated with non-steroidal anti-inflammatory drugs (NSAIDs). However, evidence in BJJ athletes remains limited, with gaps in the translation of preclinical findings to healthy athletic populations.
The prevalence of injuries in combat sports can reach 28%, with contusions and sprains being common and further exacerbating inflammation and pain. Although approximately 23.4% of athletes report cannabis use, there is a lack of randomized controlled trials (RCTs) specifically for BJJ evalua...
Conditions: Pro and Anti Inflamatory Cytokines, Pain, Sleep, Quality of Life
Interventions: CBD Isolate 100mg BID, Placebo
Mentioned entities
Related changes
Get daily alerts for ClinicalTrials.gov Studies
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from NIH.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when ClinicalTrials.gov Studies publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.